Our Mission
• Dare to cure
• united against HBV
Functional cure for hepatitis B — Unlock Lives Free From Fear
Hepatitis B affects over 300 million people worldwide, including 73 million in China, with nearly 1 million new cases each year. Yet only 25% are diagnosed, and many face social stigma that impacts work and family life.
Up to 35% of chronic cases progress to cirrhosis, and HBV is the leading cause of hepatocellular carcinoma (HCC)—the 6th most common cancer and the 4th leading cause of cancer death, often diagnosed too late. Chronic HBV accounts for 80% of HCC cases, making it a major global health threat and a critical area for therapeutic innovation.
Functional cure for Hepatits B, Multi-Billions Dollar Markets
Large patient population currently on non-curative treatment options
Company Overview
• Hepa Thera, headquartered in Shanghai, is a biotech company incubated by Fosun Pharma through its strategic corporate venture capital arm—the Fosun Health Capital New Drug Fund. Following a Flagship Pioneering-style innovation model, the fund has established a robust portfolio of cutting-edge biotech ventures, with Hepa Thera at the forefront of its commitment to pioneering therapeutic breakthroughs for liver diseases.
• At Hepa Thera, We envision a world free from liver disease, especially the hepatitis B and D. We are developing innovative therapies that are designed to address the complex and huge unmet needs of people with such liver diseases of Hepatitis B and D, MASH, and Fibrosis etc.al.
Backed by Vision, Built for Innovation
National Service Hotline
021-33670502
Working hours:
Monday to Friday: 9:00-17:30
